Thea Pharma launches resources for ophthalmologists to provide to latanoprost ophthalmic solution 0.005% to patients

(Image Credit: AdobeStock/vegefox.com)

Thea Pharma has debuted a website offering resources for ophthalmologists to provide latanoprost ophthalmic solution 0.005% (Iyuzeh) to patients

The company noted it has received feedback from ECPs about their need for patient-facing information on latanoprost ophthalmic solution as well as to simplify and visualize the prescription filling process through PhilRx.

The company noted its resources are in response to the feedback from ECPs in an effort to equip them with the tools they need to provide patients with vital education and support.

The patient-facing brochure serves as a vehicle to help ECPs review the IYUZEH information and prescription filling process with patients during and after an office visit, and the website serves as an additional resource and reference once the patient returns home.

According to the company, the website provides a number of resources, instructions, visuals, and downloads to help improve their knowledge of latanoprost ophthalmic solution.

In September 2023, Thea Pharma announced the launch and availability of latanoprost ophthalmic solution 0.005% in the US market.

Preservative-free latanoprost, launched more than 10 years ago, and is currently available in 46 countries, mostly under the brand name Monoprost, with about 1.5 million patients treated monthly, according to the company.¹

According to a news release, latanoprost ophthalmic solution is the first and only preservative-free latanoprost for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) in the U.S. In randomized, controlled clinical trials of patients with POAG or OHT with mean baseline IOP of 19-24 mmHg, the solution lowered IOP by 3–8 mmHg compared to 4–8 mm Hg by Xalatan.^2-4

References

1. Hutton D. Thea Pharma rolls out latanoprost ophthalmic solution 0.005% in the US. ophthalmologytimes. 2023;48. https://www.ophthalmologytimes.com/view/thea-pharma-rolls-out-latanoprost-ophthalmic-solution-0-005-in-the-us

2. IYUZEH (latanoprost ophthalmic solution) 0.005%. Prescribing information. Thea Pharma Inc; 2022.

3. Bacharach J, Ahmed IIK, Sharpe ED, Korenfeld MS, Zhang S, Baudouin C. Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial. Clin Ophthalmol. 2023;17:2575-2588. https://doi.org/10.2147/OPTH.S414015.

4. Rouland JF, Traverso CE, Stalmans I, et al. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013;97(2):196–200. doi:10.1136/bjophthalmol-2012-302121.